investing

Gilead Sciences' (GILD) Remdesivir Sparks Market Hope With Trial Success

Gilead's COVID-19 treatment shows efficacy in Phase 3 trial, NIAID study

Gilead Sciences (GILD, $78.67) reprised its goal as one of Wall Street's most-watched health care stocks on Wednesday after announcing positive results from trials for its COVID-19 treatment remdesivir.

Gilead announced that its COVID-19 treatment remdesivir met its primary endpoint in a National Institute of Allergy and Infectious Diseases (NIAID) clinical study. It also provided encouraging data from an open-label Phase 3 trial.

The Phase 3 trial focused on severely ill patients and found similar results for those who took five- or 10-day dosing durations, with "more than half of patients in both treatment groups (being) discharged from the hospital by Day 14."

"The study demonstrates the potential for some patients to be treated with a 5-day regimen, which could significantly expand the number of patients who could be treated with our current supply of remdesivir," Gilead Chief Medical Officer Merdad Parsey said in a release. "This is particularly important in the setting of a pandemic, to help hospitals and healthcare workers treat more patients in urgent need of care."

Later Wednesday, the U.S. Food and Drug Administration said it was in "sustained and ongoing" discussions with the drugmaker over making its COVID-19 treatment available "as quickly as possible, as appropriate." The New York Times reported that a senior administration official said remdesivir could get FDA authorization for emergency use as soon as today.

GILD stock, which has climbed 21% through April 28, versus an 11% loss for the S&P 500, was up 9% in premarket action after a trading halt for the pending news. The company's stock has climbed in 2020 amid hopes that remdesivir – which Gilead introduced years ago as a general antiviral and was previously tested as an Ebola treatment – would prove effective against the COVID-19 coronavirus.

However, the drug is of interest to more than just GILD shareholders.

Because of its potential, the broader stock market has occasionally ebbed and flowed on any shreds of information about remdesivir's performance in clinical trials. Indeed, stock-market index futures surged higher ahead of Wednesday's open following Gilead's reports.

Remdesivir was touted early as a possible game-changer in the world's battle against COVID-19. "There's only one drug right now that we think may have real efficacy. And that's remdesivir," Bruce Aylward, an international leader of the World Health Organization's joint mission to China, said Feb. 24.

The market jumped April 16 amid a STAT News report claiming success against COVID-19 in a Chicago hospital. However, stocks broadly receded April 23 after the WHO accidentally published draft documents outlining a disappointing Chinese trial – documents that Gilead said included "inappropriate characterizations of the study."

Most Popular

Yes, You Can Collect Social Security from an Ex-Spouse: Here’s How
social security

Yes, You Can Collect Social Security from an Ex-Spouse: Here’s How

It’s always smart to maximize your Social Security benefits, and if you are divorced, one way to do that might be to take them based on your ex’s earn…
May 13, 2021
Updated Exclusive Social Security Benefits Forecast: COLA Likely to Jump to 4.5% in 2022
Economic Forecasts

Updated Exclusive Social Security Benefits Forecast: COLA Likely to Jump to 4.5% in 2022

This would be the largest cost-of-living adjustment for Social Security benefits since 2008.
May 12, 2021
Child Tax Credit 2021: Who Gets $3,600? Will I Get Monthly Payments? And Other FAQs
Coronavirus and Your Money

Child Tax Credit 2021: Who Gets $3,600? Will I Get Monthly Payments? And Other FAQs

People have lots of questions about the new $3,000 or $3,600 child tax credit and the advance payments that the IRS will send to most families in 2021…
May 4, 2021

Recommended

Bonds: 10 Things You Need to Know
Investing for Income

Bonds: 10 Things You Need to Know

Bonds can be more complex than stocks, but it's not hard to become a knowledgeable fixed-income investor.
July 22, 2020
Stock Market Holidays in 2021
Markets

Stock Market Holidays in 2021

Is the stock market open today? Take a look at which days the NYSE, Nasdaq and bond markets take off in 2021.
April 26, 2021
Why I Like Ginnie Mae Funds Now
Investing for Income

Why I Like Ginnie Mae Funds Now

A portfolio of mortgages should retain their value better than ordinary bonds if interest rates rise.
February 28, 2021
2 Top-Tier T. Rowe Price Mutual Funds
mutual funds

2 Top-Tier T. Rowe Price Mutual Funds

T. Rowe Price's mutual funds typically stand out among their peers, but these two selections provide elite equity and bond exposure for this point in …
February 24, 2021